Shanghai Pharmaceuticals Holding Co has bid for Cardinal Health Inc’s China business as the U.S. company looks to sell ahead of China’s planned drug distribution reform.
Shanghai Pharma submitted two non-binding bids to buy Cardinal Health China, one of the country’s largest drug distributors, on July 21 and Sept. 15, it said in a filing with the Shanghai stock exchange on Wednesday.
The company, backed by the Shanghai government, did not disclose the financial terms but said it has not entered into exclusive talks with the seller.
Reuters first reported in July that Cardinal Health had put its China business up for sale in a deal that could fetch between $1.2 billion and $1.5 billion.
The sale has drawn keen interest from state-backed Chinese pharmaceuticals companies and private equity firms such as FountainVest, said sources with knowledge of the matter.
Cardinal’s China business, which operates 16 distribution centers in 20 cities, generated more than $3.5 billion in revenue last year, compared with $3 billion in 2015, according to its earnings report.
It has hired Lazard as an adviser for the China sale, according to the sources.
FountainVest did not respond immediately to requests for comment and Lazard declined to comment. The sources asked not to be identified because the talks are not public.
Beijing in January introduced a so-called “two-invoice” procurement system for drug distribution on a trial basis as part of a broader overhaul of the country’s fragmented healthcare sector.
Under the new system, expected to be fully implemented in 2018, drug manufacturers can only work with a single distributor that directly supplies products to healthcare facilities such as hospitals.
The policy is likely to squeeze margins for many distributors that lack links to strong manufacturers and healthcare facilities in China.
In spite of the overhaul, state-owned pharma companies with strong backing from Beijing to create “national champions” in key industries have been looking to expand.
Shanghai Pharma, for example, said in August that it was bidding for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals.
By Julie Zhu
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.